Jennifer W Chow1, Michael F Chicella1, Anthony M Christensen1, Carolyn S Moneymaker1, John Harrington1, James E Dice1. 1. Department of Pharmacy (JWC, MFC, JED), Children's Hospital of The King's Daughters, Norfolk, Virginia, Department of Pediatrics (MFC, CSM, JH), Eastern Virginia Medical School, Norfolk, Virginia, Department of Pharmaceutical Services (AMC), St. Jude Children's Research Hospital, Memphis, Tennessee.
Abstract
OBJECTIVES: Palivizumab is a monoclonal antibody approved for the prevention of serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk pediatric patients. While palivizumab is more effective if used correctly, compliance with the monthly dosing is suboptimal. We established a pharmacist-managed RSV prevention clinic in an effort to improve compliance. The primary objective of this study was to determine the impact of a pharmacist-managed RSV prevention clinic on palivizumab compliance. METHODS: A chart review was performed. Patients who received palivizumab between September 2009 and April 2012 were identified. Compliance was determined as the number of patients who received eligible doses at 28- to 30-day intervals, consecutively. RESULTS: One hundred seventy-two patients received at least 1 dose of palivizumab. An average of 92% of patients who received at least 1 dose subsequently received all doses of palivizumab during the RSV season. Of those, 88% received all eligible doses in consecutive 28-to 30-day intervals. CONCLUSION: A pharmacist-managed RSV prevention clinic can assist physicians in the prevention of RSV by increasing compliance with palivizumab dosing.
OBJECTIVES:Palivizumab is a monoclonal antibody approved for the prevention of serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk pediatric patients. While palivizumab is more effective if used correctly, compliance with the monthly dosing is suboptimal. We established a pharmacist-managed RSV prevention clinic in an effort to improve compliance. The primary objective of this study was to determine the impact of a pharmacist-managed RSV prevention clinic on palivizumab compliance. METHODS: A chart review was performed. Patients who received palivizumab between September 2009 and April 2012 were identified. Compliance was determined as the number of patients who received eligible doses at 28- to 30-day intervals, consecutively. RESULTS: One hundred seventy-two patients received at least 1 dose of palivizumab. An average of 92% of patients who received at least 1 dose subsequently received all doses of palivizumab during the RSV season. Of those, 88% received all eligible doses in consecutive 28-to 30-day intervals. CONCLUSION: A pharmacist-managed RSV prevention clinic can assist physicians in the prevention of RSV by increasing compliance with palivizumab dosing.
Authors: Rosalyn J Singleton; Dana Bruden; Lisa Brooks; Jenni DeLeon; Anna Vercelline; Jay C Butler Journal: Int J Circumpolar Health Date: 2006-02 Impact factor: 1.228
Authors: David M Scott; Steven T Boyd; Michelle Stephan; Sam C Augustine; Thomas P Reardon Journal: Am J Health Syst Pharm Date: 2006-11-01 Impact factor: 2.637